MiMedx GroupMDXG
MDXG
About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Employees: 895
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
119% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 21
59% more capital invested
Capital invested by funds: $581M [Q3] → $923M (+$342M) [Q4]
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
15% more call options, than puts
Call options by funds: $610K | Put options by funds: $529K
7% more funds holding
Funds holding: 193 [Q3] → 207 (+14) [Q4]
1.67% less ownership
Funds ownership: 66.99% [Q3] → 65.32% (-1.67%) [Q4]
25% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 65
Research analyst outlook
We haven’t received any recent analyst ratings for MDXG.
Financial journalist opinion
Positive
Zacks Investment Research
2 months ago
MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Positive
Zacks Investment Research
2 months ago
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Positive
Zacks Investment Research
2 months ago
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
MiMedx (MDXG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Positive
Zacks Investment Research
3 months ago
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
The mean of analysts' price targets for MiMedx (MDXG) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
3 months ago
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Neutral
GlobeNewsWire
3 months ago
MIMEDX's Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs' Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers.
Positive
Zacks Investment Research
3 months ago
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Seeking Alpha
3 months ago
MiMedx Group, Inc. (MDXG) Q3 2024 Earnings Call Transcript
MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Brad Bowers - Mizuho Securities Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Third Quarter 2024 Operating and Financial Results Conference Call.
Positive
Zacks Investment Research
3 months ago
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
MiMedx (MDXG) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
MIMEDX Announces Third Quarter 2024 Operating and Financial Results
Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05 , Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET
Charts implemented using Lightweight Charts™